← All trials
NCT02176122
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- Feb 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 454
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of QueenslandLead sponsor
- UQCCR, RBWHOverall official - principal investigator
- International Society of ChemotherapyCollaborator
- Australian Society for AntimicrobialsCollaborator
- Queensland Clinical Trials & Biostatistics CentreCollaborator
- Australasian Society for Infectious DiseasesCollaborator
- University of QueenslandReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.